Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

August 31, 2017

Study Completion Date

August 31, 2017

Conditions
Hidradenitis Suppurativa
Interventions
DRUG

Apremilast

"Investigational Product: Apremilast~Doses: Period A:~10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6~Period B:~30mg Twice per day, day #7 through week #24~Period C:~Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"

Trial Locations (1)

33134

Florida Academic Dermatology Centers, Coral Gables

All Listed Sponsors
lead

Florida Academic Dermatology Centers

OTHER

NCT02695212 - Single Center Study of Apremilast for the Treatment of Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter